AcquisitionsAug 6, 2026, 07:38 AM
Collegium Completes Azstarys Acquisition, Reports Q2 Net Loss of $(15.05)M
AI Summary
Collegium Pharmaceutical completed the acquisition of Azstarys on May 12, 2026, expanding its commercial presence into the ADHD market. The acquisition involved approximately $655.6 million in cash consideration, funded by existing cash and a $300 million term loan. For the second quarter of 2026, the company reported a net loss of $(15.05) million, a decrease from a net income of $11.98 million in the prior year, despite product revenues increasing to $199.88 million from $188 million. The financial results reflect significant acquisition-related expenses totaling $23.3 million for the quarter.
Key Highlights
- Collegium completed Azstarys Acquisition on May 12, 2026.
- Acquisition consideration was approximately $655.6M in cash.
- Acquisition funded by $355.6M cash on hand and $300M term loan.
- Acquired intangible assets valued at $635M; goodwill at $44.25M.
- Product revenues, net, for Q2 2026 increased to $199.88M from $188M YoY.
- Net loss for Q2 2026 was $(15.05)M, compared to net income of $11.98M YoY.
- Acquisition-related expenses totaled $23.3M for Q2 2026.
- Cash and cash equivalents decreased to $129.47M as of June 30, 2026.
Price Impact
More from COLL